U.S. Hemostats Market Size, Share & COVID-19 Impact Analysis, By Product (Active Hemostats, Passive Hemostats, Combination Hemostats, and Others), By Application (Trauma, Cardiovascular Surgery, General Surgery, Plastic Surgery, Orthopedic Surgery, Neurosurgery and Others), By End User (Hospitals & ASCs, Tactical Combat Casualty Care Centers, and Others), and Country Forecast, 2023-2030

The U.S. hemostats market size was worth USD 1.45 billion in 2022 and is projected to grow at a CAGR of 7.2% during the forecast period.

The number of surgical procedures in the U.S. has witnessed a steady growth in recent years. This is majorly due to the increasing prevalence of chronic conditions requiring surgical interventions, coupled with the rising occurrence of trauma and accidents, which further require surgical procedures.

• For instance, according to an article published in January 2023, in the U.S., a total of 35,766 fatal car accidents occurred in 2020. Additionally, 1,593,390 crashes resulted in injuries.

Thus, such a high number of road accidents has increased the need for effective blood loss management products.

On the other hand, the COVID-19 pandemic had an adverse effect on the U.S. market due to the cancellation or postponement of elective and non-essential surgeries in the country. However, with the ease in lockdown restrictions, the market regained its pace in 2021 and returned to pre-pandemic growth in 2022.

U.S. Hemostats Market Trends

Increasing Number of Hospitals and ASCs Identified as Significant Market Trend

In the U.S., the number of hospitals and ASCs is constantly increasing. This has increased the number of surgical procedures being performed at these facilities. This factor has also led to a high demand for a wide range of efficient products with strong features for managing bleeding complications during these surgical procedures.

Additionally, the number of Ambulatory Surgery Centres (ASCs) in the U.S. is also increasing at a steady pace. For instance, according to the data published by ASC Data, there were 6,179 Medicare-certified ASCs in the U.S. in 2022. This trend boosted the demand for hemostatic agents in the market. Moreover, increasing incidence of sports-related injuries and spinal ailments have also supplemented the growing need for hemostats.

U.S. Hemostats Market Growth Factors

Rising Technological Developments in Products to Propel Market Growth

As the demand for hemostatic agents is growing at a significant rate, the key players operating in the market are focusing on the development of innovative and technologically advanced products. There are several advantages that are associated with these innovative products, such as increased efficiency in achieving hemostasis, reduced risk of infections, and others. Owing to these advantages, key companies are focusing on the development and manufacturing of products having several improved features. Additionally, widening the application areas of these products can increase their demand in various surgical procedures.

• For instance, in January 2023, Grifols announced positive topline results from a phase 3b clinical trial conducted using its fibrin sealant for the treatment of surgical bleeding in pediatric patients.

According to the data published in June 2022 by the American Society for Metabolic and Bariatric Surgery, in the U.S., in 2021, the number of bariatric surgical procedures increased by 32.3% as compared to 2020.

RESTRAINING FACTORS

Clinical Limitations Associated with Product to Impede Market Growth Prospects

One of the key factors restraining the market growth is the clinical limitations associated with the use of these products during surgical procedures in the country. Limitations on the usage of these products to control the excessive bleeding despite its demonstrated effectiveness, result in the limited adoption of these products by end-users. Additionally, high cost of these products can further limit the market growth to a certain extent.

For example, according to a study published in June 2021, the cost of hemostatic agents made with micro-fibrillar collagen was higher than that of other absorbable agents. Similarly, biologically active agents, made with virus-inactivated human fibrinogen and human thrombin, were priced higher than all absorbable agents.

U.S. Hemostats Market Segmentation Analysis

By Product Analysis

Based on product, this market is segmented into passive hemostats, active hemostats, combination hemostats, and other.

The passive hemostat segment accounted for a significant U.S. hemostats market share in 2022. The segment is further categorized into plant-based, animal-based, and others. Introduction of new and innovative products, coupled with easy availability of passive hemostats, has driven the segment’s growth.

Whereas, the combination hemostat segment is anticipated to witness the fastest growth over the forecast period. The technological advancements in these products is majorly driving the segment's growth.

By Application Analysis

Based on application, this market is segmented into orthopedic surgery, neurosurgery, cardiovascular surgery, trauma, plastic surgery, general surgery, and others.

The general surgery segment captured the largest market share in 2022. An increasing number of patients undergoing several types of general surgical procedures is fueling the segment’s growth. For instance, more than 1 million breast biopsies are performed every year in the U.S.

The cardiovascular surgery segment will also show significant growth over the study period. The increasing incidence of cardiovascular diseases requiring surgical procedures is responsible for the growth of this segment. For instance, according to an article published in July 2023, approximately 200,000 heart bypass surgeries are performed every year in the U.S.

By End-User Analysis

Based on end-user, the market is segmented into tactical combat casualty care centers, hospitals & ASCs, and others.

In 2022, the hospitals & ASCs segment held the dominating market share and is estimated to continue its dominance in the U.S. market during the study period as well. Owing to the ease of accessibility to supplies required for complex surgical procedures, majority of the surgeries are conducted at hospitals across the country. In addition, increase in patient flow in ASCs in recent years is, in turn, driving the segment’s growth.

The tactical combat casualty care centers segment is estimated to grow considerably during the forecast period. The increasing need for combat activities due to rising instances of military conflict in the country is expected to boost the segment’s growth.

KEY INDUSTRY PLAYERS

The market in the U.S. shows a consolidated structure, with well-established companies, such as Johnson & Johnson Services, Inc. (MENTOR), Baxter, and BD (Becton, Dickinson, and Company) leading the market with a notable share. A strong focus on the launch of technologically advanced products, a wide product portfolio of these companies, and focus on strategic initiatives are some of the key factors contributing to their market dominance.

• For instance, in December 2021, BD acquired TissueMed, a company involved in the development of self-adhesive surgical sealant film. TissuePatch, the key product of TissueMed, claims to be useful in preventing leakages from surgical incisions.

Some other key players that are operating in the market include Stryker, Artivion, Inc., Medtronic, and others. These companies are focusing on expanding their product portfolios to enhance their market presence.

LIST OF KEY COMPANIES PROFILED:

• Baxter (U.S.)


• Integra LifeSciences (U.S.)


• Stryker (U.S)


• Artivion, Inc. (U.S.)


• Biom'up (U.S.)


• BD (Becton, Dickinson and Company) (U.S.)


• Medtronic (Ireland)


• Johnson & Johnson Services, Inc. (U.S.)


• Pfizer Inc. (U.S.)

KEY INDUSTRY DEVELOPMENTS:

• March 2023 – Axio Biosolutions’ Ax-Surgi Surgical Hemostat received the U.S. FDA 510(k) clearance. This product is chitosan-based, which can be used in controlling severe surgical bleeding.


• January 2023 – LifeGel Absorbable Surgical Hemostat, developed by Medcura, Inc., received the U.S. FDA’s Breakthrough Device Designation. This is the only product with this designation and can be used in surgical procedures where swelling cannot be tolerated. 


• February 2022 – Futura Surgicare Pvt. Ltd. introduced Hemostax (Oxidised Regenerated Cellulose). It is an absorbable hemostat that helps surgeons in efficiently control bleeding.

REPORT COVERAGE

The report provides a detailed analysis of the market. It focuses on key areas, such as top products, applications, and end-users. Additionally, it includes detailed insights on the market’s dynamics, new product launches, key industry developments, such as mergers, partnerships, & acquisitions, and the impact of COVID-19 on the market. The report also provides the competitive landscape of key companies at the U.S. level.

Report Scope & Segmentation